Answers are grounded in this paper and cite their sources.
Phase 1b/2a clinical development evaluates liver regeneration efficacy in potential drug candidates, indicating promising results.
evaluations of different lead candidates, identified darizmetinib, demonstrating dose-dependent efficacy across various disease-relevant pharmacological models.
No takes yet. Share an insight, caveat, or question.
Albrecht et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: